ClinicalTrials.gg
CompletedNCT05796206Updated Nov 2, 2026

A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus

A Phase 2 interventional study of MIL62 and placebo in Systemic Lupus Erythematosus, sponsored by Beijing Mabworks Biotech Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Beijing Mabworks Biotech Co., Ltd. · Phase 2, Interventional, and Treatment

Updated Nov 2, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Enrollment
61st of 245
123 · median 36
Started
2023
with 23 others
Phase 2
33 of 266
14 open now
Registered
84th of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 61st largest by enrollment of the 245 interventional ones that give a count, is one of 24 that started in 2023, is one of 33 in phase 2, and was the 84th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, pharmacokinetics(PK), pharmacodynamics(PD) and ADA of MIL62 compared with placebo in participants with systemic lupus erythematosus.

03

Conditions studied

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80 ;
  2. Diagnosis of systemic lupus erythematosus according to European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria ;
  3. Positive antinuclear antibodies (ANA) ≥ 1:80 at screening or positive anti- dsDNA ;
  4. Low C3 and/or low C4 complement at screening ;
  5. High disease activity at screening ;
  6. On a stable SLE treatment regimen for at least 30 days prior to the first administration;
  7. Able and willing to provide written and to comply with the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Unsufficient organ function;
  2. Received rituximab or any B-cell depleting drug within 9 months prior to the first dose;
  3. Subjects with \< 200 cells/μL;
  4. Received cyclophosphamide within 8 weeks prior to the first dose; received calcineurin inhibitors (cyclosporine, tacrolimus, etc., except for topical use) or plasma exchange therapy within 4 weeks prior to the first dose;
  5. Received a B-cell stimulating factor inhibitor such as Belimumab, and Telitacicept within 12 weeks prior to the first administration; TNF inhibitor, interleukin monoclonal antibody, JAK inhibitor, BTK inhibitor, TYK2 inhibitor, or thalidomide within 4 weeks prior to the first administration;
  6. Received live or attenuated vaccination within 28 days prior to the first administration;
  7. Participated in other clinical trials within 28 days prior to the first administration;
  8. Concomitant with other serious diseases;
  9. Positive for surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) with HBV DNA titer above the normal range; positive for virus (HCV) antibody; positive for (HIV);
  10. Subjects with known history of severe allergic reactions to humanized monoclonal antibodies MIL62 ;
  11. Breastfeeding or pregnant women;
  12. and unwillingness or impossibility to comply with a scientifically acceptable birth-control method;
  13. Other conditions unsuitable for participation in this study determined by the Investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    MIL62(Part A and B)

    Drug: MIL62

  • Placebo comparator
    Placebo (Part A and B)

    Drug: placebo

Interventions

  • DrugMIL62

    MIL62 will be administered by intravenous (IV) infusion at a dose of 1000 mg on Week (W) 1 Day (D) 1, W3D1, W25D1, W27D1, W53D1, and W55D1.

  • Drugplacebo

    Placebo will be administered by intravenous (IV) infusion at a dose of 1000 mg on Week (W) 1 Day (D) 1, W3D1, W25D1, W27D1, W53D1, and W55D1.

06

What researchers measure

Primary outcomes

  1. Part A and Part B:Percentage of participants achieving SRI-4 at Week 12

    Time frame: at Week 12

Secondary outcomes

  1. Part A and Part B:Proportion of participants achieving SRI-4 at Week 52

    Time frame: at Week 52

  2. Part A and Part B:Proportion of participants achieving SRI-4 at Week 24

    Time frame: at Week 24

  3. Part A and Part B:Proportion of participants achieving SRI-4 at Week76

    Time frame: at Week 76

  4. Part A and Part B:Change From Baseline in 24-hour urine protein in participants with elevated baseline urine protein (24-hour urine protein ≥ 0.5g) at Week 24,52,76

    Time frame: up to 76 weeks after randomization

  5. Part A and Part B:Percentage of participants who achieved or maintained a prednisone dose of ≤7.5 mg/day (or equivalent dose) during Weeks 40 to 52

    Time frame: from Week 40 to Week 52 after randomization

  6. Part A and Part B:Change From Baseline in EuroQol- 5 Dimension (EQ-5D) at Week 24, 52, 76

    Time frame: up to 76 weeks after randomization

  7. Part A and Part B:Change From Baseline in Serum Immunoglobulin Levels at Week 24 Change from baseline in the serum levels of IgG, IgA, IgM

    Time frame: up to 76 weeks after randomization

  8. Part A and Part B:Change From Baseline in biomarkers associated with disease anti-dsDNA ,complement component 3 (C3), and complement component 4 (C4)

    Time frame: up to 76 weeks after randomization

  9. Part A and Part B:Percentage of Participants with Adverse Events

    Time frame: up to 76 weeks after randomization

  10. Part A: Pharmacokinetic(PK) Parameters: AUC

    The area under the curve (AUC) of serum concentration of the drug after the administration

    Time frame: up to 76 weeks after randomization

  11. Part A: Pharmacokinetic(PK) Parameters:Cmax

    Maximum concentration(Cmax) of the drug after administration

    Time frame: up to 76 weeks after randomization

  12. Part A and Part B: Pharmacodynamics(PD) characteristics:summarizing the changes in the absolute counts and percentages of peripheral blood CD19⁺ B cells, CD3⁺CD4⁺ T cells, CD3⁺CD8⁺ T cells, NK cells, CD19⁺CD27⁺ B cells, and CD19⁺CD27- naïve B cells

    Time frame: up to 76 weeks after randomization

  13. Part Aand Part B: Anti-Drug Antibodies (ADA) will be tested and percentage of ADA positive patients will be calculated to evaluate immunogenicity of MIL62

    Time frame: up to 76 weeks after randomization

07

Study locations

1 site
  • Peking University People's Hospital
    Beijing, China
08

References and documents

Publications

  • Li Y, Shi G, Jiang G, Wei M, Liu Z, Wu Q, Nie Y, Wu R, Zhang L, Zhang H, Yang J, Liu Y, Song S, Wu X, Zheng Y, Sun L, Xie Q, Liang J, Li F, Li Z; BeSolve Investigators Group. Efficacy and safety of obinutuzumab beta in patients with active systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Rheumatol. 2026 Nov 8:S2665-9913(26)00315-2. doi: 10.1016/S2665-9913(26)00315-2. Online ahead of print. PubMed 43000040 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Nov 2024, 17 months.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 47. This study's 17 months is below that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 55.

Primary completion moved once since we started tracking on Sep 25, 2026: Feb 2026 → Nov 2024, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2023
First posted
Apr 3, 2023
StartActual
May 26, 2023
Primary completionActual
Nov 21, 2024was Feb 2026
CompletionActual
Jul 2, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 2, 2026
Primary completion
Feb 2026→Nov 21, 2024 (actual)
Nov 2, 2026
Enrollment
120 (estimated)→123 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Active, not recruiting→Completed
    Primary completion Feb 2026→Nov 21, 2024 (now actual)
    Enrollment 120 (estimated)→123 (actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05796206
Lead sponsor
Beijing Mabworks Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Apr 3, 2023
Start date
May 26, 2023
Primary completion
Nov 21, 2024
Completion
Jul 2, 2026
Last update
Nov 2, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD20 Monoclonal Antibody MIL62

Start the discussion